Patents by Inventor Eric Walter Theodore Chojnicki

Eric Walter Theodore Chojnicki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS INCLUDING A RECOMBINANT HUMAN MAB THAT PROMOTES CNS REMYELINATION
    Publication number: 20200247883
    Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like.
    Type: Application
    Filed: September 23, 2019
    Publication date: August 6, 2020
    Inventors: Elliott A. Gruskin, Arthur E. Warrington, Allan J. Bieber, Moses Rodriguez, Eric Walter Theodore Chojnicki
  • Compositions and Methods including a Recombinant Human MAB that Promotes CNS Remyelination
    Publication number: 20180179277
    Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like.
    Type: Application
    Filed: September 1, 2017
    Publication date: June 28, 2018
    Inventors: Elliott A. Gruskin, Arthur E. Warrington, Allan J. Bieber, Moses Rodriguez, Eric Walter Theodore Chojnicki
  • Compositions and methods including a recombinant human MAB that promotes CNS remyelination
    Patent number: 9751943
    Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: September 5, 2017
    Assignees: ACORDA THERAPEUTICS, INC., MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Elliott A. Gruskin, Arthur E. Warrington, Allan J. Bieber, Moses Rodriguez, Eric Walter Theodore Chojnicki
  • Compositions and Methods including a Recombinant Human MAB that Promotes CNS Remyelination
    Publication number: 20150299316
    Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like.
    Type: Application
    Filed: January 23, 2015
    Publication date: October 22, 2015
    Inventors: Elliott A. Gruskin, Arthur E. Warrington, Allan J. Bieber, Moses Rodriguez, Eric Walter Theodore Chojnicki